Menlo Park, CA (September 19, 2016) – Adicet Bio, Inc. today announced that it has been named by FierceBiotech as one of 2016's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

“We are honored to be selected to the “Fierce 15” class of 2016,” said Aya Jakobovits, Ph.D., President and Chief Executive Officer of Adicet Bio. “We are committed to advancing our novel off-the-shelf immune cell-based platform and proprietary immunotherapies directed to MHC-peptide complexes to generate first-in-class therapies for patients suffering from cancer, autoimmunity and other diseases indications.”

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s fourteenth annual Fierce 15 selection. An internationally recognized daily report reaching a network of over 275,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day’s top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

About FierceBiotech

FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at https://pages.questexweb.com/FierceBiotech-Newsletter-Signup.html?_ga=1.2394681.800155757.1473173899.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a privately held, preclinical stage biotechnology company that is engaged in the development of cutting-edge immunotherapies for cancer and other disease indications, with a focus on novel universal immune cell therapies (uICT). Adicet’s wholly owned subsidiary, Applied Immune Technologies, Ltd. is developing immunotherapies directed to the disease-specific peptide-MHC complexes associated with different disease indications. Adicet Bio is located in Menlo Park, California.

Contact:

Aya Jakobovits, Ph.D.
President and Chief Executive Officer
Adicet Bio, Inc.
info@adicetbio.com

Media Contact:

Joan Kureczka
Kureczka/Martin Associates
Ph: 415.821.2413
joan@kureczka-martin.com